Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025.

The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day. Investors can access the call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with accompanying slides will be available on the company's investor relations website.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 333 restricted stock units (RSUs) to one newly-hired employee as of July 31, 2025. The RSUs will vest over three years, with 33 1/3% vesting annually on the grant date anniversary.

The grant was made under the company's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs include accelerated vesting provisions in case of a change in control event followed by qualifying employment termination.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has announced the granting of 666 restricted stock units (RSUs) to two newly-hired employees as of June 30, 2025.

The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting annually. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). Additionally, the RSUs include provisions for immediate full vesting in case of employment termination under specific conditions following a change in control event.

Karyopharm Therapeutics (KPTI), a commercial-stage pharmaceutical company focused on innovative cancer therapies, announced its senior management team will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 5, 2025, at 3:10 p.m. ET in New York. Investors can access a live webcast of the presentation with accompanying slides through the 'Events & Presentations' section of Karyopharm's investor relations website. The presentation will also be available for replay after the event.

Karyopharm Therapeutics (NASDAQ: KPTI), a commercial-stage pharmaceutical company focused on cancer therapies, has granted 566 restricted stock units (RSUs) to two new employees as of May 31, 2025. The RSUs were awarded under the company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with one-third vesting annually on the grant date anniversary. Full vesting acceleration applies if employment terminates for good reason or without cause within one year of a change in control event.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's senior management team will engage in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available after the event.

Karyopharm Therapeutics (KPTI) will present new data on selinexor in treating myelofibrosis at the 2025 EHA Annual Meeting. The Phase 2 XPORT-MF-035 trial results showed promising outcomes in hard-to-treat patients:

- 67% of selinexor-treated patients achieved ≥25% spleen volume reduction vs 38% in physician's choice (PC) group - 33% achieved ≥35% spleen volume reduction vs 13% in PC group - Higher mean hemoglobin levels and lower transfusion rates - Greater reductions in key cytokines (IL-6, IL-8, TNFa, hepcidin)

The trial involved 24 patients (12 per arm), with 6 crossing over from PC to selinexor. Common side effects included decreased weight (50%), anemia (25%), and nausea (33%). Notably, no treatment discontinuations occurred in the selinexor arm due to adverse events.

Karyopharm Therapeutics (KPTI) reported Q1 2025 financial results and clinical progress. Total revenue was $30.0M, with U.S. XPOVIO net product revenue of $21.1M, down from $26.0M in Q1 2024 due to a $5.0M increase in product return reserve. The company reaffirmed its 2025 guidance of $140-155M in total revenue. Key clinical developments include: The Phase 3 SENTRY trial in myelofibrosis passed its futility analysis and is ~80% enrolled, with completion expected in June/July 2025. New Phase 2 data showed promising results for selinexor in treating myelofibrosis, with 67% of patients achieving ≥25% spleen volume reduction. The company reported a net loss of $23.5M ($2.77 per share) and had $70.3M in cash as of March 31, 2025. Management is exploring alternatives to extend cash runway beyond early Q4 2025.

Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss financial results and provide company updates.

Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live audio webcast with accompanying slides will be available on the company's investor relations website, with an archived version accessible approximately two hours after the event.